微流控精子处理对囊胚整倍体率的影响:与密度梯度离心法的同胞卵母细胞双盲前瞻性随机临床试验
该单中心大学附属不孕症诊所的同胞卵母细胞随机对照试验纳入106例18-42岁接受新鲜体外受精及胚胎植入前遗传学检测的患者,共1442枚成熟卵母细胞,分别用微流控或密度梯度离心处理的精子注射。微流控组囊胚整倍体率未显著改善,但受精率显著更高。
要点
- 微流控组每成熟卵母细胞的囊胚整倍体率为22.9%,对照组为20.5%,无显著差异。
- 微流控组每注射成熟卵母细胞的受精率为76.0%,显著高于对照组的69.9%。
- 两组每注射成熟卵母细胞的高质量囊胚形成率及冷冻胚胎总数相似。
核心结论
- 在这项同胞卵母细胞研究中,与密度梯度离心相比,微流控处理未改善胚胎整倍体率,但受精率显著更高。
研究设计与样本
- 同胞卵母细胞随机对照试验,单中心大学附属不孕症诊所开展。
- 共纳入106例18-42岁接受新鲜体外受精治疗周期并行胚胎植入前遗传学检测的患者,贡献1442枚成熟卵母细胞。
- 精子样本分为两份,分别用微流控装置和密度梯度离心处理,注射入同胞卵母细胞。
- 主要结局为胚胎整倍体率;次要结局包括受精率、高质量囊胚形成率和持续妊娠率。
- 临床试验注册号NCT04744025。
主要发现
- 每成熟卵母细胞的囊胚整倍体率:微流控组22.9% vs 密度梯度离心组20.5%,无显著差异。
- 每活检胚胎的囊胚整倍体率:微流控组53.0% vs 密度梯度离心组45.7%,两组相似。
- 每注射成熟卵母细胞的受精率:微流控组76.0% vs 密度梯度离心组69.9%,微流控组显著更高。
- 每注射成熟卵母细胞的高质量囊胚形成率及冷冻胚胎总数两组相似。
- 两组无囊胚可活检的患者数及无整倍体胚胎的患者数均无差异。
局限性
- 在男性因素不孕和复发性妊娠丢失亚组中,研究把握度不足以检测整倍体率、受精率、囊胚形成率及冷冻囊胚总数的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the euploidy rates among blastocysts created from sibling oocytes injected with sperm and processed using microfluidics or density gradient centrifugation. DESIGN: Sibling oocyte randomized controlled trial. SETTING: Single university-affiliated infertility practice. PATIENTS: A total of 106 patients aged 18-42 years undergoing fresh in vitro fertilization treatment cycles with preimplantation genetic testing between January 2021 and April 2022 contributed 1,442 mature oocytes, which were injected with sperm and processed using microfluidics or density gradient centrifugation. INTERVENTION(S): The sperm sample is divided and processed using a microfluidics device and density gradient centrifugation for injection into sibling oocytes. MAIN OUTCOME MEASURE(S): The primary outcome was the embryo euploidy rate. Secondary outcomes included fertilization, high-quality blastulation, and ongoing pregnancy rates. RESULT(S): The blastocyst euploidy rate per mature oocyte was not significantly different in the study group compared with the control group (22.9% vs. 20.5%). The blastocyst euploidy rate per biopsied embryo was also similar between the 2 groups (53.0% vs. 45.7%). However, the fertilization rate per mature oocyte injected was found to be significantly higher in the study group compared with the control group (76.0% vs. 69.9%). The high-quality blastulation rate per mature oocyte injected was similar between the 2 groups, as was the total number of embryos frozen. There were no differences in the number of participants with no blastocysts for biopsy or the number of participants with no euploid embryos between the 2 groups. Among the male factor infertility and recurrent pregnancy loss subgroups, there were no differences in euploidy rates, fertilization rates, blastulation rates, or total numbers of blastocysts frozen, although the study was underpowered to detect these differences. Seventy-seven patients underwent frozen embryo transfer; there were no significant differences in pregnancy outcomes between the 2 groups. CONCLUSION(S): Microfluidics processing did not improve embryo euploidy rates compared with density gradient centrifugation in this sibling oocyte study, although fertilization rates were significantly higher. CLINICAL TRIAL REGISTRATION NUMBER: NCT04744025.
引用
- Godiwala P, Kwieraga J, Almanza E, et al. The impact of microfluidics sperm processing on blastocyst euploidy rates compared with density gradient centrifugation: a sibling oocyte double-blinded prospective randomized clinical trial. Fertil Steril. 2024. PMID: 38367686. doi:10.1016/j.fertnstert.2024.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。